The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer

Korábbi kezelés

• Concurrent acute or chronic psychiatric disorders;
• Patients receiving sleep medication;
• Prior participation in other clinical drug trials;
• Concurrent acute or chronic psychiatric disorders;
• Patients receiving sleep medication;
• Prior participation in other clinical drug trials;
• Concurrent acute or chronic psychiatric disorders;
• Patients receiving sleep medication;
• Prior participation in other clinical drug trials;
• Concurrent acute or chronic psychiatric disorders;
• Patients receiving sleep medication;
• Prior participation in other clinical drug trials;
• Concurrent acute or chronic psychiatric disorders;
• Patients receiving sleep medication;
• Prior participation in other clinical drug trials;

Más betegség

• Presence of other malignant tumors or malignant diseases within 3 years;
• Presence of other malignant tumors or malignant diseases within 3 years;
• Presence of other malignant tumors or malignant diseases within 3 years;
• Presence of other malignant tumors or malignant diseases within 3 years;
• Presence of other malignant tumors or malignant diseases within 3 years;

Laborértékek

• Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) fusion and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
• EGFR-sensitizing mutation and/or ALK fusion and/or ROS1 fusion-positive;

Egyéb

• Symptomatic brain metastasis;
• Inability to complete scale assessments.
  • Cohort 2:
• Symptomatic brain metastasis;
• Inability to complete scale assessments.
  • Cohort 3:
• Symptomatic brain metastasis;
• Inability to complete scale assessments.
  • Cohort 4:
• Inability to complete scale assessments.
  • Cohort 5:
• Symptomatic brain metastasis;
• Inability to complete scale assessments.

• Age ≥ 18 years old;
• Histologically confirmed diagnosis of NSCLC;
• Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
• Treatment naïve;
• Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);
• Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
• Informed consent to participate in the study;
• Age ≥ 18 years old;
• Histologically confirmed diagnosis of SCLC；
• Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;
• ECOG PS of 0-1;
• Treatment naïve;
• Presence of at least one measurable lesion according to the RECIST v1.1 ;
• Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
• Informed consent to participate in the study;
• Age ≥18 years old;
• Pathologically diagnosed as NSCLC;
• Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;
• At least one measurable lesion can be evaluated according to the RECIST v1.1;
• Treatment naïve;
• Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy as neoadjuvant therapy;
• Cardiopulmonary function can withstand surgery;
• Informed consent to participate in the study.
• Age ≥ 18 years old;
• Pathologically diagnosed as NSCLC;
• Pathologically stage confirmed as early stage of IA-IIIA;
• Available for tumor tissue samples;
• Treatment naïve;
• Receiving radical surgery;
• Informed consent to participate in the study;
• Age ≥ 18 years old;
• Histologically confirmed diagnosis of NSCLC;
• Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
• ECOG PS of 0-1;
• Treatment naive;
• Presence of at least one measurable lesion according to the RECIST v1.1;
• Receiving targeted therapy or combination with chemotherapy;
• Informed consent to participate in the study;
• Driver gene-positive.

A regiszterben nem jelölt feltételek

• Cohort 1: